Active Clinical Studies

Protocol Title: Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer

Principal Investigator: Mohammad Memon, MD

Indication: Locally Advanced (inoperable) or metastatic HR+/HER2- breast cancer 

Study Description: The purpose of this study is to learn more about treatment with an experimental drug called capivasertib, added to a standard of care treatment fulvestrant + CDK4/6i (palbociclib or ribociclib) for patients with advanced breast cancer and to better understand the studied disease and associated health problems.
 

Protocol Title: A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Subjects with Intermediate Risk (IR) Non-Muscle Invasive Bladder Cancer (NMIBC)

Principal Investigator: David C Lieber, MD   Indication: Intermediate Risk (IR) Non-Muscle Invasive Bladder Cancer (NMIBC)   Study Description: No medicines are approved for treatment of intermediate risk non-muscle invasive bladder cancer. Therefore, the purpose of this research study is to investigate how well tolerated and effective nadofaragene firadenovec (the investigational study drug) is at preventing IR-NMIBC from coming back after removal.

Protocol Title: A Phase 3, Randomized, Double Blind, Placebo Controlled Study of PF-06821497 (Mevrometostat) With Enzalutamide in Metastatic Castration Resistant Prostate Cancer (Nickname: MEVPRO-2)

Principal Investigator: David Lieber, MD

Indication: Metastatic Castration Resistant Prostate Cancer, prior to having received next-generation androgen deprivation therapy (e.g. apalutamide, enzalutamide, darolutamide and abiraterone)

Study Description: The purpose of this study is to explore whether a combination of the investigational drug mevrometostat and enzalutamide will work better than taking enzalutamide alone in the treatment of metastatic castration resistant prostate cancer (mCRPC).  

Protocol Title: A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)

Principal Investigator: Mohammad Memon, MD   Indication: First Line in Metastatic Squamous Non-Small Cell Lung Cancer    Study Description: The purpose of this research is to compare the effectiveness and safety of rilvegostomig plus chemotherapy to that of a standard treatment for metastatic, Squamous, NSCLC (pembrolizumab plus chemotherapy). The chemotherapy you will receive is carboplatin plus paclitaxel or carboplatin plus nab-paclitaxel (nanoparticle albumin-bound paclitaxel) depending on the decision of your doctor. We are also doing this study to better understand metastatic NSCLC and associated health problems. One of the wayswe will do this is to look at various measurable characteristics (biomarkers) in your body as indicators of health, disease or response to treatment.  

Protocol Title: A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)

Principal Investigator: Mohammad Memon, MD   Indication: First Line in Metastatic Non-Squamous Non-Small Cell Lung Cancer    Study Description: The purpose of this research is to compare the effectiveness and safety of rilvegostomig plus chemotherapy to that of a standard treatment for metastatic, Non-Squamous, NSCLC (pembrolizumab plus chemotherapy). The chemotherapy you will receive is carboplatin plus pemetrexed or cisplatin plus pemetrexed. This study is also testing the effectiveness of the diagnostic test used to assess the biomarker PD-L1 to identify metastatic NSCLC participants most likely to benefit from treatment with rilvegostomig in combination with chemotherapy.

Protocol Title: CLINICAL BIOSPECIMEN COLLECTION TO SUPPORT BIOMARKER RESEARCH

Principal Investigator: Robert Johnson, MD

Indication: Various Cancers

Study Description: To collect the biological specimens to use towards biomarker development and other technologies or treatment for oncology patients.